Recent Publications

Cardiovascular diseases/diabetes

  • Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. Kleijer BC, Heerdink ER, Egberts TC et al., J Clin Psychopharmacol, 2010, 30(5): 526-30.
  • Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. Heintjes EM, Thomsen TL, Penning-van Beest FJ et al., Adv Ther, 2010, 27(4): 211-22.
  • Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure. De Peuter OR, Souverein PC, Klungel OH et al., Eur J Heart Fail, 2010, in press.
  • Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Peters BJ, Rodin AS, Klungel OH et al., Pharmacogenet Genomics, 2010, in press.
  • Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. Garcia Rodriguez LA, Herings R and Johansson S, Pharmacoepidemiol Drug Saf, 2010, in press.

Musculoskeletal diseases

  • Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Verdel BM, Souverein PC, Egberts TC et al., Bone, 2010, 47(3): 604-9.
  • Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Pouwels S, Lalmohamed A, Souverein P et al., Osteoporos Int, 2010, in press.
  • Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study. Arbouw ME, Movig KL, van Staa TP et al., 2010, in press.

Respiratory diseases

  • Three-year dispensing patterns with long-acting inhaled drugs in COPD: A database analysis. Penning-van Beest F, van Herk-Sukel M, Gale R et al., Respir Med, 2010, in press.

Research support

  • Design and evaluation of a semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project. Avillach P, Joubert M, Thiessard F et al., Stud Health Technol Inform, 2010, 160(Pt 2): 1085-9.

Other

  • Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study. Kröger E, van Marum R, Souverein P and Egberts T, Drugs Aging, 2010, 27(8): 663-75.
  • Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. Sasané R, Hodgkins P and Meijer W, Curr Med Res Opin, 2010, 26(11): 2565-74.
  • A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness. Refoios Camejo R, McGrath C and Herings R, Health Policy, 2010, in press.

Other questions? Please send us an e-mail: pharmo@pharmo.nl